INSMED Inc (INSM)
INSMED Inc (INSM) from its SEC filings: 2025 revenue $606.4 million (+67% vs the year before), net margin -210%, free cash flow -$967.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $606.4 million |
| Revenue growth | +67% |
| Net income | -$1.3 billion |
| Net margin | -210.5% |
| Free cash flow | -$967.6 million |
| Diluted EPS | $-6.42 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +296% |
| Cash | $544.8 million |
| Long-term debt | $543.5 million |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.